JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...

European Medicines Agency (EMA) granted priority medicine (PRIME) designation to Intellia Therapeutics' (NASDAQ:NTLA) in vivo CRISPR gene editing therapy NTLA-2002 to treat patients with hereditary ...

Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass ...

Intellia Therapeutics Inc (NTLA) showcases promising clinical progress and financial resilience amidst evolving market ...

NTLA-2002 is a wholly owned investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for this potentially life-threatening disease. Patient screening is ...

In the HAELO trial, the firm will randomize 60 HAE patients to NTLA-2002 or placebo and compare the number of inflammatory attacks.

Variation in the frequency of hereditary angioedema attacks between weeks five and 28 will be the trial's primary endpoint.

Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).

Credit: Intellia Therapeutics. US-based biotechnology company Intellia Therapeutics has begun the Phase III HAELO clinical trial of NTLA-2002, an investigational in-vivo gene editing therapy for ...